Scholarlink

Introduction <p>Inhaled therapies are essential for managing asthma and chronic obstructive pulmonary disease (COPD), but device choice carries environmental consequences. Inhaler devices influence climate impact; propellant-based metered-dose inhalers (MDIs) have substantially higher carbon footprints than non-propellant inhalers (NPIs). Ireland has committed to net-zero greenhouse gas emissions by 2050, making prescribing practices a relevant focus for mitigation.</p> Aim <p>To describe national dispensing patterns of inhaled respiratory medicines and estimate associated CO₂-equivalent (CO₂e) emissions in Irish primary care, 2020–2022.</p> Method <p>We analysed Health Service Executive–Primary Care Reimbursement Service (HSE-PCRS) dispensing data for inhaled respiratory medicines (ATC R03) products. Items were classified as MDIs or NPIs. Trends of inhalers use were expressed as year-on-year inhalers dispensed. We conducted scenario analysis in which 10%, 25%, and 50% of 2022 MDIs use were replaced with NPIs to calculate the reduction in carbon emissions. Notably, PCRS schemes cover ~ 43% of the Irish population (predominantly older adults and a lower income group).</p> Results <p>Between 2020 and 2022, a total of 9.94 million inhalers were dispensed under HSE-PCRS schemes, with annual volumes rising from 3.04 million (2020) to 3.60 million (2022)<b>.</b> MDIs increased from 1.50 million (2020) to 1.79 million (2021) and 1.95 million (2022), while NPIs declined − 15.7% in 2021 and then rebounded + 26.8% in 2022. The MDIs share of all inhalers changed from 49.2% (2020) to 57.9% (2021) to 54.2% (2022) for which estimated MDIs carbon emissions were 28.6, 34.6, and 37.6&#xa0;kt CO₂e, respectively. This emission was accounted for 95–96% of inhaler-related emissions annually. In scenario analyses, replacing 10%, 25%, and 50% of 2022 MDIs use with NPIs resulted in estimated emission reduction of ~ 3.6, 8.9, and 17.9&#xa0;kt CO₂e, respectively.</p> Conclusion <p>The results show how MDIs influence the carbon footprint of the health sector and&#xa0;they encourage healthcare providers to support sustainable alternatives. When clinically appropriate, choosing sustainable devices provides significant, short-term CO2 savings without sacrificing treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimation of carbon emissions from inhaled respiratory medicines in Ireland: a cross-sectional study from a national pharmacy claims database from 2020 to 2022

  • 期刊论文

  • 发表日期：

    2025年11月14日

查看全文
  • Hafsa Kanwal,
  • Umm-E-Kalsoom,
  • Amjad Khan,
  • Theo Ryan,
  • James Quinn,
  • Cristin Ryan

摘要

Introduction

Inhaled therapies are essential for managing asthma and chronic obstructive pulmonary disease (COPD), but device choice carries environmental consequences. Inhaler devices influence climate impact; propellant-based metered-dose inhalers (MDIs) have substantially higher carbon footprints than non-propellant inhalers (NPIs). Ireland has committed to net-zero greenhouse gas emissions by 2050, making prescribing practices a relevant focus for mitigation.

Aim

To describe national dispensing patterns of inhaled respiratory medicines and estimate associated CO₂-equivalent (CO₂e) emissions in Irish primary care, 2020–2022.

Method

We analysed Health Service Executive–Primary Care Reimbursement Service (HSE-PCRS) dispensing data for inhaled respiratory medicines (ATC R03) products. Items were classified as MDIs or NPIs. Trends of inhalers use were expressed as year-on-year inhalers dispensed. We conducted scenario analysis in which 10%, 25%, and 50% of 2022 MDIs use were replaced with NPIs to calculate the reduction in carbon emissions. Notably, PCRS schemes cover ~ 43% of the Irish population (predominantly older adults and a lower income group).

Results

Between 2020 and 2022, a total of 9.94 million inhalers were dispensed under HSE-PCRS schemes, with annual volumes rising from 3.04 million (2020) to 3.60 million (2022). MDIs increased from 1.50 million (2020) to 1.79 million (2021) and 1.95 million (2022), while NPIs declined − 15.7% in 2021 and then rebounded + 26.8% in 2022. The MDIs share of all inhalers changed from 49.2% (2020) to 57.9% (2021) to 54.2% (2022) for which estimated MDIs carbon emissions were 28.6, 34.6, and 37.6 kt CO₂e, respectively. This emission was accounted for 95–96% of inhaler-related emissions annually. In scenario analyses, replacing 10%, 25%, and 50% of 2022 MDIs use with NPIs resulted in estimated emission reduction of ~ 3.6, 8.9, and 17.9 kt CO₂e, respectively.

Conclusion

The results show how MDIs influence the carbon footprint of the health sector and they encourage healthcare providers to support sustainable alternatives. When clinically appropriate, choosing sustainable devices provides significant, short-term CO2 savings without sacrificing treatment.